Your browser doesn't support javascript.
loading
Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
Li, Min-Ran; Li, Jin-Zhong; Li, Jie-Ying; Wang, Cun-Chuan; Yuan, Rui-Kun; Ye, Li-Hong; Liu, Yun-Yan; Liang, Xu-Jing; Zhang, Hai-Cong; Liu, Zhi-Quan; Zeng, Dong-Yu; Zhang, Xue-Dong; Wang, De-Hua; Li, Jun-Qing; Li, Tao-Yuan; Yang, Liu; Cao, Yang; Pan, Yun; Lin, Xun-Ge; Pan, Calvin Q; Dai, Er-Hei; Dong, Zhi-Yong.
Afiliación
  • Li MR; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China, muziran@126.com.
  • Li JZ; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Li JY; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Wang CC; Bariatric and Metabolic Surgery Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Yuan RK; Division of Infectious Disease, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.
  • Ye LH; Division of Pathology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Liu YY; Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Liang XJ; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Zhang HC; Division of Pathology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Liu ZQ; Division of Pathology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Zeng DY; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Zhang XD; Autobio Diagnostics Co., Ltd, Zhengzhou City, China.
  • Wang DH; Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Li JQ; Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
  • Li TY; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Yang L; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Cao Y; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Pan Y; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Lin XG; Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Pan CQ; Department of Infectious Disease, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Dai EH; Division of Gastroenterology and Hepatology, NYU Langone Health, NYU Grossman School of Medicine, New York, New York, USA.
  • Dong ZY; Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
Obes Facts ; 16(5): 427-434, 2023.
Article en En | MEDLINE | ID: mdl-37231905
INTRODUCTION: The prevalence of non-alcoholic fatty liver disease (NAFLD) in non-lean patients is significantly increased, and obesity significantly increases the risk of cirrhosis and HCC in NAFLD patients. However, whether there is a difference in clinical manifestations of NAFLD between overweight and obesity remains unclear. The objective of this study was to assess the clinical and histological features of NAFLD among a non-lean population. METHODS: Current study enrolled consecutive non-lean (body mass index [BMI] >23 kg/m2) patients with NAFLD and available liver biopsy results. Patients were stratified by BMI into two groups for the comparison of their clinical and histological variables, which included the overweight (BMI 23∼<28 kg/m2) and the obese (BMI ≥28 kg/m2). Risk factors for moderate to severe fibrosis (stage >1) were also analyzed through the logistic regression model. RESULTS: Among 184 non-lean patients with metabolic-associated fatty liver disease enrolled, 65 and 119 were overweight and obese, respectively. Patients in the obesity group had a significantly lower level of gamma-glutamyl transpeptidase, higher levels of platelet, glucose, prothrombin time, and more common of moderate to severe inflammatory activity when compared to those in the overweight group. However, a significant low frequency of moderate to severe fibrosis was found in the obesity group versus the overweight group (19.33% vs. 40.00%, p = 0.002). Binary logistics regression analysis of fibrosis found that aspartate transaminase (AST), BMI, alanine transaminase (ALT), and cholesterol (CHOL) were independent predictors for moderate to severe fibrosis in non-lean patients with NAFLD. Compared with the traditional fibrosis-4 (AUC = 0.77) and aminotransferase to platelet ratio index (AUC = 0.79) indexes, the combined index based on AST, BMI, ALT, and CHOL was more accurate in predicting moderate to severe fibrosis in non-lean patients with NAFLD (AUC = 0.87). CONCLUSIONS: Clinical and histological features differed between obesity and overweight patients with NAFLD. When compared to the traditional serum markers, the combination index including AST, BMI, ALT, and CHOL provided a better model to predict moderate to severe fibrosis in non-lean patients with NAFLD.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Enfermedad del Hígado Graso no Alcohólico / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Obes Facts Asunto de la revista: METABOLISMO Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Enfermedad del Hígado Graso no Alcohólico / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Obes Facts Asunto de la revista: METABOLISMO Año: 2023 Tipo del documento: Article